Tagged with MS

IMS Health South Africa Mrs. Reid, how would you define and describe the generic part of the South African pharmaceutical market? Linda Reid: South Africa is very much a branded generics market, and not a commodity generics market. The brand is important in South Africa and a lot of our generics are not International…

IMS Health Hungary IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from the other markets in the region? I believe none of the countries of the region is having a good time…

IMSA - Innovative Medecine South Africa Ms Beaumont, can you describe the association to our readers and its main objectives? Innovative Medicines South Africa (IMSA) represents manufacturers of research-based medicines, ie they market the products of their own research. Many of our members do have generic medicines in their product portfolio, and we believe there is…

Pharmstandard You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the company developed since the IPO? We were honored on the London Stock Exchange as the Best Newcomer of 2007, and…

IMS Romania We understand that you have been heading IMS Health in Romania for 10 years now, which has been quite a trajectory. Therefore, can you highlight the key milestones and achievements for IMS Romania in this past decade? IMS is partner of choice for industry because of its combination of data…

CMS Russia How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the last five years, we have been truly active in the Russian life sciences market. In general, CMS has adopted a…

MSD pharmaceuticals Pvt. Ltd. While your appointment as Managing Director was not a long time ago, you immediately faced the big task to oversee one of the most complicated corporate mergers the local Indian drug industry has seen in recent years. How challenging was the integration of Fulford and Organon for you? One of…

IMS Russia You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market? For the IMS, in terms of strategic development, this was certainly a significant acquisition—because afterwards, the organization became the leading…

MSD Russia You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation prior to the interview, you mentioned that there has been a bit of a transition and adjustment period. How is…

IMS Health Netherlands IMS Health sets itself apart because of its global reach, while mastering local expertise. Clearly, every market is one of a kind. What is so particular about the Dutch market? There are quite a few particularities. When we discuss the value of the pharmaceutical market in the Netherlands for example,…

IMS Health Malaysia You spent most of your career in the pharmaceutical industry with Bristol Meyers Squibb and earlier on for NV Organon which you joined in 1998. In 2007 you left to join the world of consultancy, how useful was this insider knowledge to your work and what is it like now…

Merck Sharp & Dohme Limited (MSD) You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the UK operations? As General Manager of the Merck/Schering-Plough Joint Venture in the US, I was responsible for the commercial operations…